Free Trial

Provexis (PXS) Competitors

GBX 0.55 0.00 (0.00%)
As of 04/17/2025

PXS vs. ALK, CLCO, ICON, PAA, GEL, MMP, AAL, CCL, SAVE, and GNK

Should you be buying Provexis stock or one of its competitors? The main competitors of Provexis include Alkemy Capital Investments (ALK), CloudCoCo Group (CLCO), Iconic Labs (ICON), 22532 (PAA.L) (PAA), Greka Engineering & Technology (GEL), Marwyn Management Partners (MMP), Anglo American (AAL), Carnival Co. & (CCL), Savannah Energy (SAVE), and Greene King (GNK). These companies are all part of the "transportation" industry.

Provexis vs.

Alkemy Capital Investments (LON:ALK) and Provexis (LON:PXS) are both small-cap financial services companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.

1.5% of Alkemy Capital Investments shares are owned by institutional investors. Comparatively, 7.9% of Provexis shares are owned by institutional investors. 43.7% of Alkemy Capital Investments shares are owned by insiders. Comparatively, 21.6% of Provexis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alkemy Capital Investments has a net margin of 0.00% compared to Provexis' net margin of -73.10%. Alkemy Capital Investments' return on equity of 181.08% beat Provexis' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkemy Capital InvestmentsN/A 181.08% -258.00%
Provexis -73.10%-68.68%-56.14%

In the previous week, Alkemy Capital Investments' average media sentiment score of 0.00 equaled Provexis'average media sentiment score.

Company Overall Sentiment
Alkemy Capital Investments Neutral
Provexis Neutral

Alkemy Capital Investments has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Provexis has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.

Alkemy Capital Investments received 92 more outperform votes than Provexis when rated by MarketBeat users. Likewise, 76.88% of users gave Alkemy Capital Investments an outperform vote while only 64.21% of users gave Provexis an outperform vote.

CompanyUnderperformOutperform
Alkemy Capital InvestmentsOutperform Votes
153
76.88%
Underperform Votes
46
23.12%
ProvexisOutperform Votes
61
64.21%
Underperform Votes
34
35.79%

Provexis has higher revenue and earnings than Alkemy Capital Investments. Provexis is trading at a lower price-to-earnings ratio than Alkemy Capital Investments, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkemy Capital InvestmentsN/AN/A-£1.29M-£14.59-6.85
Provexis£846.98K15.24-£619.15K-£0.03-20.85

Summary

Alkemy Capital Investments beats Provexis on 7 of the 12 factors compared between the two stocks.

Get Provexis News Delivered to You Automatically

Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PXS vs. The Competition

MetricProvexisDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£12.91M£2.13B£5.31B£2.52B
Dividend Yield5.06%2.92%5.47%4.80%
P/E Ratio-20.854.3321.94130.68
Price / Sales15.24478.32380.94235,142.89
Price / CashN/A10.2538.3128.34
Price / Book64.126.146.454.43
Net Income-£619,153.31£20.70B£3.22B£5.88B
7 Day PerformanceN/A1.55%5.85%2.86%
1 Month Performance10.00%-3.00%-9.58%-0.97%
1 Year Performance-8.33%93.87%11.85%22.26%

Provexis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PXS
Provexis
N/AGBX 0.55
flat
N/AN/A£12.91M£846,984.38-20.854Gap Up
ALK
Alkemy Capital Investments
N/AGBX 100
-9.1%
N/A+17.6%£8.82MN/A-6.8525,500Gap Down
CLCO
CloudCoCo Group
N/AGBX 0.10
+21.2%
N/AN/A£742,000.00£27.84M-0.35125Gap Up
High Trading Volume
ICON
Iconic Labs
N/AN/AN/AN/A£586,000.00£600,855.00-15.003Gap Up
High Trading Volume
PAA
22532 (PAA.L)
N/AN/AN/AN/A£0.00N/A0.004,100Gap Up
High Trading Volume
GEL
Greka Engineering & Technology
N/AN/AN/AN/A£0.00N/A0.002,110
MMP
Marwyn Management Partners
N/AN/AN/AN/A£0.00N/A0.001,660
AAL
Anglo American
2.3759 of 5 stars
GBX 2,024.50
-0.5%
GBX 2,698.33
+33.3%
-7.1%£30.79B£36.94B-18.64129,700Positive News
CCL
Carnival Co. &
N/AGBX 1,226.50
-0.9%
N/A+19.4%£22.16B£32.78B11.1240,000
SAVE
Savannah Energy
N/AGBX 7.75
+3.3%
N/AN/A£10.17B£18.46B-5.0311,100Positive News
GNK
Greene King
N/AN/AN/AN/A£2.63B£2.22B21.941,010High Trading Volume

Related Companies and Tools


This page (LON:PXS) was last updated on 4/20/2025 by MarketBeat.com Staff
From Our Partners